SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
SpringWorks Therapeutics, Inc. (SWTX) , forward earnings yield 3.67%.
Criteria proven by this page:
- VALUE (90/100, Pass) — analyst target implies upside (+33%).
- Forward P/E 27.3
- Analyst consensus target $62.50 (+33% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 57/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
90/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — SWTX
Valuation Multiples
P/E (TTM)0.0
Forward P/E27.3
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio18.18
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-3.48
Forward EPS (Est.)$1.72
Book Value / Share$0.00
Revenue / Share$2.58
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield3.67%
Dividend Yield0.00%
Analyst Target$62.50 (+33%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2017 |
$-0.11 |
$0.00 |
$-4.64M |
- |
| 2018 |
$-0.80 |
$0.00 |
$-17.81M |
- |
| 2019 |
$-1.27 |
$0.00 |
$-54.76M |
- |
| 2020 |
$-1.02 |
$35M |
$-44.24M |
-126.4% |
| 2021 |
$-3.57 |
$0.00 |
$-173.21M |
- |
| 2022 |
$-5.14 |
$6.15M |
$-274.16M |
-4460.1% |
| 2023 |
$-5.15 |
$5.45M |
$-325.1M |
-5968.5% |
| 2024 |
$-3.48 |
$191.59M |
$-258.13M |
-134.7% |
